TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Corporation announced positive Phase 2a trial results showing 64% overall survival at 12 months for atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, nearly double the 35% benchmark from standard of care. The company plans to initiate its pivotal Phase 3 trial (MAPKeeper 301) in mid-2026, with FDA and EMA alignment already secured on trial design.

Insights
IMRX   positive

The company reported exceptional clinical trial results with 64% 12-month overall survival, nearly double the standard of care benchmark of 35%. The drug demonstrated consistent survival advantages across multiple time points (6, 9, and 12 months), favorable tolerability profile, and the company has secured regulatory alignment for a pivotal Phase 3 trial expected to begin mid-2026, representing significant clinical and commercial progress.